- 米国企業
- Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc.CMRA
| 2022年 12月31日 |
---|
Revenue | 633,102 |
---|
Cost of revenue | 210,390 |
---|
Research and development | 2 |
---|
General and administrative | 11 |
---|
Total operating expenses | 12 |
---|
Loss from operations | -11,970,015 |
---|
Change in fair value of derivative warrant liabilities | 2 |
---|
Reverse recapitalization issuance costs in excess of gross proceeds | 7 |
---|
Common stock purchase agreement issuance costs | 1 |
---|
Interest expense | 20,391 |
---|
Other expense, net | -426,666 |
---|
Total other (expense) income, net | -6,034,083 |
---|
Net loss and comprehensive loss | -18 |
---|
Less: accretion of convertible preferred stock to redemption value | 373,856 |
---|
Net loss attributable to common stockholders or unit holders | -18,377,954 |
---|
Earnings Per Share, Basic | -1.76 |
---|
Earnings Per Share, Diluted | -1.76 |
---|